Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$72 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.4
Industry P/E
--
EV/EBITDA
-1.1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-3.3
Face value
--
Shares outstanding
36,674,400
CFO
$-1,073.70 Mln
EBITDA
$-1,195.89 Mln
Net Profit
$-1,388.03 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Inovio Pharmaceuticals (INO)
| 12.8 | 4.8 | 7.6 | -74.5 | -55.9 | -61.9 | -32.7 |
|
BSE Sensex
| 4.9 | 0.4 | 6.7 | 6.3 | 16.2 | 18.3 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Inovio Pharmaceuticals (INO)
| -69.8 | -67.3 | -68.7 | -43.6 | 168.2 | -17.5 | -3.1 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Inovio Pharmaceuticals (INO)
|
2.1 | 71.9 | 0.3 | -96.5 | -27,122.8 | -0.4 | -- | 1.4 |
| 50.2 | 7,821.1 | 1,208.8 | 131.7 | 13.4 | 6.3 | 60.1 | 3.9 | |
| 128.3 | 8,290.2 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 149.0 | 7,242.1 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 51.3 | 10,001.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 45.5 | 11,009.2 | 2,298.9 | 643.6 | 35.4 | 29.2 | 18.4 | 5.2 | |
| 53.9 | 6,507.3 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14 | 13.5 | |
| 313.5 | 8,891.5 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.6 | 15.0 | |
| 26.9 | 10,016.6 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 128.2 | 12,524.1 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.9 | 4.9 |
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious... diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the University of Pennsylvania, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania. Address: 660 West Germantown Pike, Plymouth Meeting, PA, United States, 19462 Read more
CEO, President & Director
Dr. Jacqueline E. Shea Ph.D.
CEO, President & Director
Dr. Jacqueline E. Shea Ph.D.
Headquarters
Plymouth Meeting, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Inovio Pharmaceuticals Inc (INO) stood at $ 159,123 Mln as on 31-Mar-25
The share price of Inovio Pharmaceuticals Inc (INO) is $2.07 (NASDAQ) as of 24-Jun-2025 15:41 EDT. Inovio Pharmaceuticals Inc (INO) has given a return of -55.93% in the last 3 years.
Inovio Pharmaceuticals Inc (INO) has a market capitalisation of $ 72 Mln as on 23-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Inovio Pharmaceuticals Inc (INO) is 1.39 times as on 23-Jun-2025, a 50% discount to its peers’ median range of 2.79 times.
Since, TTM earnings of Inovio Pharmaceuticals Inc (INO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Inovio Pharmaceuticals Inc (INO) and enter the required number of quantities and click on buy to purchase the shares of Inovio Pharmaceuticals Inc (INO).
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the University of Pennsylvania, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania. Address: 660 West Germantown Pike, Plymouth Meeting, PA, United States, 19462
The CEO & director of Dr. Jacqueline E. Shea Ph.D.. is Inovio Pharmaceuticals Inc (INO), and CFO & Sr. VP is Dr. Jacqueline E. Shea Ph.D..
There is no promoter pledging in Inovio Pharmaceuticals Inc (INO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,260
|
|
|
1,128
|
|
|
991
|
|
|
988
|
|
|
870
|
|
|
829
|
|
|
809
|
|
|
742
|
|
|
664
|
| Inovio Pharmaceuticals Inc. (INO) | Ratios |
|---|---|
|
Return on equity(%)
|
-0.38
|
|
Operating margin(%)
|
-27122.76
|
|
Net Margin(%)
|
-34079.58
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Inovio Pharmaceuticals Inc (INO) was $0 Mln.
$0.14
(
